US equities |
SPCX $167.41 ▲+5.31% NVDA $236.30 ▲+1.00% MU $1,066.38 ▼-0.79% TSLA $378.43 ▲+2.12% MSFT $526.38 ▲+1.71% SNDK $1,710.64 ▼-0.54% INTC $117.36 ▼-1.65% META $744.35 ▲+2.23%
FinancialContent

BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

66.68 -0.57 (-0.85%)
Delayed Quote Updated: 12:46 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BridgeBio Pharma, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
15 16 Next >
News headline image
BridgeBio, A Top 3% Biotech, Just Snagged A $310 Million Deal; Will Shares Break Out? ↗
BridgeBio will receive a tiered royalty on sales that begins at the low-30% range. 
Via Investor's Business Daily
News headline image
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
Recap: BridgeBio Pharma Q4 Earnings ↗
 
Via Benzinga
News headline image
BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
Reliance Steel & Aluminum Posts Upbeat Earnings, Joins JFrog, AppLovin, Shake Shack And Other Big Stocks Moving Higher On Thursday ↗
U.S. stocks were mostly higher, with the Dow Jones index gaining more than 150 points on Wednesday. 
Via Benzinga
Topics Stocks
News headline image
BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Inc. (NASDAQ: BBIO) is a Stock Spotlight on 1/9
Via Investor Brand Network
News headline image
2 Biotechs That Could Get Bought Out in 2024 ↗
These two biotechs have been frequent visitors to the buyout-rumor mill and for good reason. 
Via The Motley Fool
News headline image
BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
3 Groundbreaking Biotech Stocks to Invest in Now ↗
These are several biotech companies for investors seeking unique opportunities for great returns within the industry. 
Via InvestorPlace
News headline image
7 Exciting Stocks Poised for Explosive Growth in Key Sectors ↗
These stocks to buy for growth already have a strong growth story. If they reach their potential investors could see some dynamic returns. 
Via InvestorPlace
News headline image
BridgeBio Pharma Secures up to $1.25 Billion of Capital from Blue Owl and CPP Investments to Accelerate the Development and Launch of Genetic Medicines
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio announces FDA clearance of IND application for BBO-8520, a first-in-class direct inhibitor of KRASG12C (ON)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
3 Russell 2000 Stocks That Are About to Get Absolutely Crushed ↗
The Russell 2000 has only begun closing its wide gap with other indices, but investors should be weary of these three stocks to sell. 
Via InvestorPlace
News headline image
BridgeBio Announces First Child Dosed in PROPEL 3, its Phase 3 Clinical Trial for Infigratinib in Children with Achondroplasia
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Announces Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
BridgeBio Pharma to Present Additional Data from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American Heart Association (AHA) Scientific Sessions 2023
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
Why Is Biomarin & BridgeBio Pharma Rival Lumos Pharma Stock Trading Higher Today? ↗
Lumos Pharma Inc (NASDAQ: LUMO) announced that topline results from its Phase 2 OraGrowtH210 dose-finding trial and its Phase 2 OraGrowtH212 Pharmacokinetic/Pharmacodynamic (PK/PD) trial met all... 
Via Benzinga
News headline image
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
Rare Disease Player BridgeBio Pharma's Upside Potential Is Significant According to Citi Analyst - Here's Why ↗
Citi initiated coverage on BridgeBio Pharma Inc (NASDAQ: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, noting an optimistic outlook on the stock. 
Via Benzinga
News headline image
BridgeBio Pharma Reports Third Quarter 2023 Financial Results and Business Update
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
Why BridgeBio Pharma Was a Healthy Stock Today ↗
One of the best-performing biotechs on the stock market this year gets a bullish nod from a researcher. 
Via The Motley Fool
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
15 16 Next >